Literature DB >> 15961774

How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.

Wolfgang Wick, Michael Weller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15961774     DOI： 10.1200/JCO.2004.00.8417

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

1.  Infections in neuro-oncology.

Authors:  P Gaviani; A Silvani; E Lamperti; A Botturi; G Simonetti; I Milanesi; D Ferrari; A Salmaggi
Journal:  Neurol Sci       Date:  2011-11       Impact factor: 3.307

2.  Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years.

Authors:  Dorothee Koch; Wolfgang Wick
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

Review 3.  Chemotherapy for malignant gliomas.

Authors:  Christine Marosi
Journal:  Wien Med Wochenschr       Date:  2006-06

4.  Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.

Authors:  Katherine Riccione; Carter M Suryadevara; David Snyder; Xiuyu Cui; John H Sampson; Luis Sanchez-Perez
Journal:  J Vis Exp       Date:  2015-02-16       Impact factor: 1.355

5.  Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

Authors:  Duane A Mitchell; Xiuyu Cui; Robert J Schmittling; Luis Sanchez-Perez; David J Snyder; Kendra L Congdon; Gary E Archer; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; Roger E McLendon; David A Reardon; James J Vredenburgh; Darell D Bigner; John H Sampson
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

6.  Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

Authors:  Luis A Sanchez-Perez; Bryan D Choi; Gary E Archer; Xiuyu Cui; Catherine Flores; Laura A Johnson; Robert J Schmittling; David Snyder; James E Herndon; Darell D Bigner; Duane A Mitchell; John H Sampson
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

7.  Extended-schedule dose-dense temozolomide in refractory gliomas.

Authors:  A Berrocal; P Perez Segura; M Gil; C Balaña; J Garcia Lopez; R Yaya; J Rodríguez; G Reynes; O Gallego; L Iglesias
Journal:  J Neurooncol       Date:  2009-08-08       Impact factor: 4.130

8.  Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.

Authors:  C G Robinson; J M Palomo; G Rahmathulla; M McGraw; J Donze; L Liu; M A Vogelbaum
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

Review 9.  The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.

Authors:  Wei Wei; Xin Chen; Ximeng Ma; Dawei Wang; Zongze Guo
Journal:  J Neurooncol       Date:  2015-09-03       Impact factor: 4.130

10.  Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.

Authors:  Stefano Dall'oglio; Anna D'Amico; Fabio Pioli; Milena Gabbani; Felice Pasini; Maria Grazia Passarin; Andrea Talacchi; Sergio Turazzi; Sergio Maluta
Journal:  J Neurooncol       Date:  2008-08-08       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.